Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT-1: Tasisulam-sodium vs Paclitaxel in Metastatic Melanoma
NCT01006252Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2009
- Primary completion
- Mar 2011
- Modality
- Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of tasisulam in melanoma, sponsored by Eli Lilly and Company. Started Dec 2009; status: terminated.
02
Drugs
tasisulam
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01006252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006252.